跳至主要内容
临床试验/NCT05867784
NCT05867784已完成不适用

Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease

Second Affiliated Hospital of Wenzhou Medical University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2021年4月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
1
主要终点
Serum 25 (OH) D level

研究概览

简要总结

It is uncertain whether vitD3 supplementation is beneficial for the remission of Crohn's disease (CD). The effects of vitD3 supplements on the efficacy of ustekinumab in Chinese CD patients were retrospectively analyzed. Methods: Patients with moderate to severe CD were recorded. These patients were initially treated with UST. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of UST and continued throughout the follow-up period. Disease activity was assessed using Harvey Bradshaw Index.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
15 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • moderate-to-severe CD
  • Treated with Ustekinumab

排除标准

  • had recent supplementation of vitD3
  • had cognitive/developmental disorders that affected their ability to complete the study procedures
  • had medical illness or therapies potentially affecting bone, nutrition or growth status
  • unknown or untested baseline serum 25(OH)D level

结局指标

主要结局

Serum 25 (OH) D level

时间窗: 24 weeks

Vitamin D deficiency is defined as serum 25 (OH) D level\<20 μ g/L

disease activity

时间窗: 24weeks

Harvey Bradshaw Index,mild: 0 to 8, moderate: 9 to 16, severe: 17 to 25

次要结局

  • Serum 25 (OH) D level(8 weeks)

研究者

发起方
Second Affiliated Hospital of Wenzhou Medical University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验